Bausch + Lomb
Logotype for Bausch + Lomb Corporation

Bausch + Lomb (BLCO) investor relations material

Bausch + Lomb Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Bausch + Lomb Corporation
Q3 2026 earnings summary28 Oct, 2026

Executive summary

  • Q3 revenue was $1.375B, up 7% reported and 8% at constant currency; adjusted EBITDA rose 34% to $325M and all three segments grew.

  • Full-year 2026 revenue and adjusted EBITDA guidance increased on Q3 strength and an improved outlook for the remainder of the year.

  • Performance marked a fourth consecutive quarter meeting Investor Day commitments; interim CEO priorities include profitability, efficiency, disciplined innovation investment and Vision 2027 targets.

Financial highlights

  • Q3 revenue rose $94M YoY; volume added $63M and pricing $31M, partly offset by $6M of FX headwind and $2M from divestitures and discontinuations.

  • GAAP operating income was $155M versus $95M; attributable net income was $32M versus a $28M loss, and adjusted net income was $123M versus $66M.

  • Adjusted gross margin increased 300 bps to 64.7%, including a one-time ~$14M tariff refund; excluding the refund, margin was 63.6%.

  • Q3 operating cash flow was $233M and free cash flow was $178M after $55M of capex; 9M operating cash flow reached $418M.

Outlook and guidance

  • FY26 revenue guidance rose to $5.450B–$5.550B, with constant-currency growth of 6.1%–8.0%; underlying outlook increased $15M, partly offset by $5M lower FX tailwinds.

  • FY26 adjusted EBITDA guidance increased $65M to $1.090B–$1.140B; midpoint implies ~20.3% margin and 25% growth.

  • FY26 assumptions include adjusted gross margin of 62.5%–63.0%, net interest expense of ~$365M, adjusted tax rate of ~18% and capex of ~$285M.

  • Management remains focused on meeting or exceeding three-year Investor Day targets; the 2028 adjusted EBITDA margin target is 23%.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Bausch + Lomb earnings date

Logotype for Bausch + Lomb Corporation
Q4 202617 Feb, 2027
Bausch + Lomb
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Bausch + Lomb earnings date

Logotype for Bausch + Lomb Corporation
Q4 202617 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Bausch + Lomb Corporation is a global healthcare company specializing in eye health products. The company offers a wide range of products across three primary segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. Its portfolio includes contact lenses, lens care solutions, prescription eye medications, over-the-counter eye care products, and surgical devices for cataract, vitreoretinal, and refractive procedures. The company is headquartered in Vaughan, Canada, and its shares are listed on the NYSE (New York Stock Exchange).